LRP6 and coronary artery disorder: Another study by the same group showed that that the mice with the human LRP6R611C mutation developed modest dyslipidemia but advanced proliferative CAD, which could be reversed by enhancing canonical Wnt signals in LRP6 with Wnt3a injections [25].